| 1. |
- Andlin-Sobocki, P, et al.
(författare)
-
Cost of affective disorders in Europe
- 2005
-
Ingår i: VALUE IN HEALTH. - 1098-3015. ; 8:6, s. A210-A210
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)
|
|
| 2. |
- Andlin-Sobocki, P, et al.
(författare)
-
Cost of addiction in Europe
- 2005
-
Ingår i: European journal of neurology. - : Wiley. - 1351-5101 .- 1468-1331. ; 1212 Suppl 1, s. 28-33
-
Tidskriftsartikel (refereegranskat)
|
|
| 3. |
- Andlin-Sobocki, P, et al.
(författare)
-
Cost of affective disorders in Europe
- 2005
-
Ingår i: European journal of neurology. - : Wiley. - 1351-5101 .- 1468-1331. ; 1212 Suppl 1, s. 34-38
-
Tidskriftsartikel (refereegranskat)
|
|
| 4. |
- Andlin-Sobocki, P, et al.
(författare)
-
Cost of disorders of the brain in Europe
- 2005
-
Ingår i: European journal of neurology. - : Wiley. - 1351-5101 .- 1468-1331. ; 1212 Suppl 1, s. 1-
-
Tidskriftsartikel (refereegranskat)
|
|
| 5. |
- Andlin-Sobocki, P, et al.
(författare)
-
Cost of psychotic disorders in Europe
- 2005
-
Ingår i: European journal of neurology. - : Wiley. - 1351-5101 .- 1468-1331. ; 1212 Suppl 1, s. 74-77
-
Tidskriftsartikel (refereegranskat)
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
- Kobelt, Gisela, et al.
(författare)
-
The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data.
- 2008
-
Ingår i: Scandinavian Journal of Rheumatology. - : Informa UK Limited. - 1502-7732 .- 0300-9742. ; 37:1, s. 62-71
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: To estimate the cost-effectiveness of treating ankylosing spondylitis (AS) with infliximab (Remicade(R)) in Spain for up to 40 years. Methods: A previously published disease model was adapted to the Spanish setting using resource consumption from a cross-sectional burden of an illness study in 601 patients in Spain. Cost-effectiveness estimates were based on a placebo-controlled clinical trial as well as an open clinical study in Spain. In the model, patients with insufficient response to treatment at 12 weeks [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <4 or >/=50% reduction] discontinue treatment. The results are presented in 2005 euros, from societal and health-care payer perspectives. Results: In the societal perspective, infliximab treatment dominates standard treatment in both analyses. In the perspective of the health-care system, with the assumption that, over the long term, functional ability of patients on treatment would decline at half the natural rate, the cost per quality-adjusted life year (QALY) gained was estimated at EUR 22 519 (double-blind trial) and EUR 8866 (open study). Assuming that patients' function on treatment remains stable, the cost-effectiveness ratios are EUR 15 157 and EUR 5307, respectively. Under the most conservative assumption (no effect of treatment on progression), the ratios are EUR 31 721 and EUR 13 659, respectively. In addition, the results are sensitive to the time horizon and discontinuation rates. Conclusions: Our results indicate that infliximab therapy for patients with active AS should be cost-effective both in the societal perspective (dominating) and in the perspective of the health-care system (ranges from EUR 5300 to EUR 32 000 per QALY) in Spain.
|
|
| 12. |
|
|
| 13. |
|
|
| 14. |
- Olesen, J, et al.
(författare)
-
Cost of disorders of the brain in Denmark
- 2008
-
Ingår i: Nordic journal of psychiatry. - : Informa UK Limited. - 1502-4725 .- 0803-9488. ; 62:2, s. 114-120
-
Tidskriftsartikel (refereegranskat)
|
|
| 15. |
- Olesen, J, et al.
(författare)
-
Funding of headache research in Europe
- 2007
-
Ingår i: Cephalalgia : an international journal of headache. - : SAGE Publications. - 0333-1024. ; 27:9, s. 995-999
-
Tidskriftsartikel (refereegranskat)abstract
- Migraine costs European Society ¬27 billion per year. Other headaches may account for a similar amount. Given this enormous impact, the question arises as to whether the funding of research efforts in this field are sufficient. A recent European study called the Resource Allocation to Brain Research in Europe (RABRE) examined funding of brain research. Identified charities and Government agencies in Europe filled out a questionnaire regarding their funding of brain diseases. Industry spending was evaluated by three different previously validated methods. In the present report, detailed results are presented for migraine and other headaches. In 2004, migraine research was funded by nearly €315 million. Of this, €308 million was invested by the pharmaceutical industry, whereas public funding was estimated at €7 million. No funding was identified for non-migraine headache disorders. Of the public spending, €714 000 came from private foundations. There was a very large difference between different European countries in the funding of headache research. When public funding was compared with the cost of different brain disorders, migraine funding was in the middle range. This was due to relatively large industry funding. Compared with societal costs, migraine received the least public funds amongst all brain disorders, i.e. 0.025%. We conclude that migraine attracts reasonable interest from the pharmaceutical industry, but Governmental and charity funding is extremely low and no funding was identified for non-migraine headache disorders. Considering the huge economic impact of these disorders, public funding of research into migraine and other headaches should be greatly increased in the future.
|
|
| 16. |
|
|
| 17. |
- Pugliatti, M, et al.
(författare)
-
Cost of disorders of the brain in Italy
- 2008
-
Ingår i: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. - : Springer Science and Business Media LLC. - 1590-1874. ; 29:2, s. 99-107
-
Tidskriftsartikel (refereegranskat)
|
|
| 18. |
|
|
| 19. |
- Sillanpaa, M, et al.
(författare)
-
Costs of brain disorders in Finland
- 2008
-
Ingår i: Acta neurologica Scandinavica. - : Hindawi Limited. - 1600-0404 .- 0001-6314. ; 117:3, s. 167-172
-
Tidskriftsartikel (refereegranskat)
|
|
| 20. |
|
|
| 21. |
|
|
| 22. |
|
|
| 23. |
- Sobocki, P, et al.
(författare)
-
Cost of depression in Europe
- 2006
-
Ingår i: The journal of mental health policy and economics. - 1091-4358. ; 9:2, s. 87-98
-
Tidskriftsartikel (refereegranskat)
|
|
| 24. |
- Sobocki, P, et al.
(författare)
-
Estimation of the cost of MS in Europe: extrapolations from a multinational cost study
- 2007
-
Ingår i: Multiple sclerosis (Houndmills, Basingstoke, England). - : SAGE Publications. - 1352-4585 .- 1477-0970. ; 13:8, s. 1054-1064
-
Tidskriftsartikel (refereegranskat)abstract
- The present study aims at estimating the total cost of MS in Europe based on actual cost data from nine countries and published epidemiological evidence. The epidemiological data are reported as 12 months prevalence estimates and cost data calculated as annual cost per patient at given levels of disease severity. Cost data are extrapolated to the rest of Europe based on a model, using economic indexes adjusting for price level differences in different sectors between countries. The aggregated annual cost estimates are presented in Euro for 2005. In 28 European countries with a population of 466 million, an estimated 380 000 individuals are affected by MS. The total annual cost of MS in Europe is estimated at 12.5 billion in year 2005, corresponding to a cost of 27 per European inhabitant. Direct costs represent slightly more than half of the total cost (6.0 billion). Informal care is estimated at 3.2 billion, and indirect costs due to morbidity at 3.2 billion. Thus, the largest component of costs is found outside the formal health care sector. Although our model appears to predict costs reasonably well, when comparing to previous national studies not included in the estimates, there are considerable uncertainties when extrapolating cost data across countries even within Europe. These weaknesses can only be overcome by collecting primary data. Multiple Sclerosis 2007; 13: 1054—1064. http://msj.sagepub.com
|
|
| 25. |
|
|
| 26. |
|
|
| 27. |
|
|
| 28. |
|
|
| 29. |
- Sobocki, P., et al.
(författare)
-
Resource allocation to brain research in Europe (RABRE)
- 2006
-
Ingår i: The European journal of neuroscience. - : Blackwell Publishing Ltd. - 1460-9568 .- 0953-816X. ; 24:10, s. 2691-2693
-
Tidskriftsartikel (refereegranskat)abstract
- This article is a markedly condensed summary of a longer report [Resource allocation to brain research in Europe (RABRE), part 2] that is simultaneously published on line: (i) as supplementary material linked to this European Journal of Neuroscience article (http://www.blackwell-synergy.com/loi/ejn) and (ii) on the website of the European Brain Council (http://www.europeanbraincouncil.org/ publications). We have recently shown that brain diseases account for 35% of the overall disease burden and cost European society almost €400 billion per year (a billion is understood to mean one thousand million throughout this report). The aim of the present study was to estimate funding for brain research in Europe and the cost-benefit of further investments in this area of research. The assessment of funding included public sources (governmental agencies plus charities) and industry funding. The assessment of publicly financed research support for brain research was based on a comprehensive survey, and industry investment in brain research was assessed based on published data on pharmaceutical development. The total funding of brain research in Europe was estimated at €4.1 billion in 2005, of which public grants amounted to <€900 million. Thus, industry funding accounted for 79%. Although cancer only incurred 50% of the cost of brain diseases in 2005, public grants for cancer research were almost twice as high as the public financial support of brain research. US-based funding of brain research was almost four times higher than European funding. We assessed the cost-benefit of further investment in brain research using different methods. They all showed that increased investment in brain research is likely to be highly cost-effective. We conclude that European spending on brain research, particularly public spending, is low compared to other fields of research and to the US, and that increased investment in brain research seems warranted.
|
|
| 30. |
|
|
| 31. |
- Sobocki, P, et al.
(författare)
-
Resource use and costs associated with patients treated for depression in primary care.
- 2006
-
Ingår i: The European journal of health economics : HEPAC : health economics in prevention and care. - : Springer Science and Business Media LLC. - 1618-7598.
-
Tidskriftsartikel (refereegranskat)abstract
- We investigated medical resource consumption, productivity loss and costs associated with patients treated with antidepressants for depression in primary care in Sweden. Patients on treatment for depression were followed naturalistically for six months, and data on patients' characteristics, daily activity and resource-use were collected. The total cost per patient was estimated at 5,500 (95%CI 5,000-6,100) over six months in 2005 prices. Direct costs were estimated at 1,900 ( 1,700-2,200), 35% of total costs, and indirect costs at 3,600 ( 3,100-4,100), 65% of total costs. The cost for antidepressants represented only 4% of the total costs. We conclude that the burden of depression is high, both to the individual as well as to wider society, and there seems to be a particular need for therapies that have the potential to improve productivity in depressed patients.
|
|
| 32. |
|
|
| 33. |
- Sobocki, P, et al.
(författare)
-
The economic burden of depression in Sweden from 1997 to 2005
- 2007
-
Ingår i: European psychiatry : the journal of the Association of European Psychiatrists. - : Cambridge University Press (CUP). - 0924-9338. ; 22:3, s. 146-152
-
Tidskriftsartikel (refereegranskat)abstract
- BackgroundDepression is one of the most common causes of disability and is associated with substantial reductions in the individual's quality of life. The aim of this study was to estimate the economic burden of depression to Swedish society from 1997 to 2005.Materials and MethodsThe study was conducted in a cost-of-illness framework, measuring both the direct cost of providing health care to depressive patients, and the indirect costs as the value of production that is lost due to morbidity or mortality. The costs were estimated by a prevalence and top-down approach.ResultsThe cost of depression increased from a total of €1.7 billion in 1997 to €3.5 billion in 2005, representing a doubling of the burden of depression to society. The main reason for the cost increase is found in the significant increase in indirect costs due to sick leave and early retirement during the past decade, whereas direct costs were relatively stable over time. In 2005, indirect costs were estimated at €3 billion (86% of total costs) and direct costs at €500 million (16%). Cost of drugs was estimated at €100 million (3% of total cost).ConclusionThe cost of depression is substantial to society and the main cost driver is indirect costs due to sick leave and early retirement. The cost of depression has doubled during the past eight years making it a major public health concern for the individuals afflicted, carers and decision makers.
|
|
| 34. |
- Sobocki, P, et al.
(författare)
-
The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression.
- 2006
-
Ingår i: International journal of clinical practice. - : Hindawi Limited. - 1368-5031 .- 1742-1241. ; 60:7, s. 791-8
-
Tidskriftsartikel (refereegranskat)abstract
- The aim of the present study was to determine the magnitude of the impact of treating depression to full remission on cost and health-related quality of life. In a naturalistic longitudinal survey recordings of resource use and quality of life were carried out among depressed patients treated with antidepressant therapy in 56 Swedish primary care clinics. We found that a total of 52% of the patients achieved full remission during the study period. Remitting patients had, on average, three outpatient visits less than non-remitting patients (p < 0.01), 22 fewer sick leave days (p = 0.01), which translated into a significantly lower total cost (Euro 2700) compared with non-remitting patients (p < 0.01). Health-related quality-of-life scores improved by 40% for remitting patients when compared with non-remitting ones (p < 0.01). We conclude that remission has a substantial health economic impact on patients treated for depression, which further strengthens the importance of aiming for full remission in the treatment of depression.
|
|
| 35. |
|
|
| 36. |
- Vodusek, DB, et al.
(författare)
-
COST OF DISORDERS OF THE BRAIN IN SLOVENIA
- 2008
-
Ingår i: ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL. - 1318-0347. ; 77, s. II5-II11
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 37. |
|
|
